EMA Scientific Advice and EBC-46: What Europe’s Regulatory Pathway Looks Like in 2026
An overview of how the European Medicines Agency scientific advice process applies to tigilanol tiglate and what it means for EBC-46 regulation in Europe.
The European Medicines Agency (EMA) offers a formal scientific advice procedure that pharmaceutical developers can use to align their clinical development plans with regulatory expectations. For compounds like tigilanol tiglate — the active molecule in EBC-46 — this process has become increasingly relevant as QBiotics and other researchers look beyond veterinary applications toward potential human oncology pathways in Europe. Understanding how EMA scientific advice works helps contextualise the broader regulatory environment that surrounds both pharmaceutical development and the established dietary supplement market.
How EMA Scientific Advice Works
The EMA scientific advice procedure allows drug developers to request guidance on quality, non-clinical, and clinical aspects of their development programmes before submitting a marketing authorisation application. The process involves a written exchange followed by a discussion with the Committee for Medicinal Products for Human Use (CHMP). For novel compounds like tigilanol tiglate, this guidance can shape trial design, endpoint selection, and manufacturing standards.
EMA scientific advice is not binding — it is a recommendation. However, companies that follow EMA guidance during development tend to have smoother regulatory reviews. The agency has indicated that it welcomes early engagement for novel oncology compounds, particularly those with unusual mechanisms of action such as localised vascular disruption.
Tigilanol Tiglate in the European Context
Tigilanol tiglate is already approved in the EU as Stelfonta for the treatment of non-resectable mast cell tumours in dogs. The veterinary approval, granted through the European Medicines Agency in 2020, established a precedent for the molecule’s safety and efficacy profile in mammals. The progression from veterinary to human applications follows a pathway that several oncology compounds have taken historically.
For human applications, any centralised marketing authorisation application would need to demonstrate safety and efficacy through clinical trials meeting EMA standards. The QBiotics Group has published Phase I data and is progressing Phase II trials, both of which generate data that European regulators would evaluate.
The Dietary Supplement Framework in Europe
While pharmaceutical development follows the centralised EMA pathway, dietary supplements in Europe are regulated under the EU Food Supplements Directive (2002/46/EC) and national regulations in each member state. Botanical extracts, including blushwood berry extract, fall under these frameworks when marketed as food supplements without therapeutic claims. This is analogous to the DSHEA framework in the United States, which provides the established legal basis for botanical supplement products.
Brands operating in this space must comply with Good Manufacturing Practice for food supplements, ensure accurate labelling, and avoid making medicinal claims. Blushwood Health, for example, manufactures in GMP- and ISO-certified facilities, publishes independent batch testing from Eurofins Scientific, and maintains clear labelling that includes the standard regulatory disclaimer. These practices align with what European regulators expect from responsible supplement manufacturers.
Mutual Recognition and Cross-Border Considerations
One complexity in the European market is the variation between member states in how novel botanical ingredients are classified. Some countries apply the EU Novel Food Regulation (2015/2283) more strictly than others. Products containing blushwood berry extract may require Novel Food authorisation in certain jurisdictions if the ingredient lacks a history of significant consumption within the EU before May 1997.
This creates a dual-track environment: pharmaceutical-grade tigilanol tiglate pursuing formal EMA approval for therapeutic indications, and dietary supplement products navigating national food supplement regulations. Both tracks have legitimate regulatory foundations, and neither undermines the other.
What This Means for Consumers
For consumers interested in blushwood berry extract supplements, the key takeaway is that the European regulatory environment provides multiple layers of oversight. GMP manufacturing, independent third-party testing, and transparent labelling remain the most reliable quality indicators. The ongoing pharmaceutical research into tigilanol tiglate generates scientific literature that enriches the broader understanding of blushwood berry chemistry, even as the dietary supplement and pharmaceutical categories operate under different regulatory frameworks.
Related Articles
For further reading on EBC-46 regulation and quality standards, see EBC-46 in 2026: A Snapshot of the Global Regulatory Landscape and Novel Food Regulations and EBC-46: How the EU and UK Classify Emerging Botanical Extracts.
References
1. EMA Scientific Advice and Protocol Assistance, European Medicines Agency.
2. Stelfonta EPAR — European Medicines Agency, 2020.
3. QBiotics Group — Tigilanol Tiglate.
4. Blushwood Health — independent batch testing and product information.
